Skip to main content

Table 2 Correlation between H3S10ph levels of PRM and DRM, ≤4 vs >4 cm

From: p38-MAPK/MSK1-mediated overexpression of histone H3 serine 10 phosphorylation defines distance-dependent prognostic value of negative resection margin in gastric cancer

Total (n = 101)

H3S10 phosphorylation level of PRM ≤4 cm (n = 48)

p value

H3S10 phosphorylation level of PRM >4 cm (n = 53)

p value

Low (%), n = 28

Int. (%), n = 14

High (%), n = 6

Low (%), n = 48

Int. (%), n = 5

High (%), n = 0

WHO classification

 WD

1 (3.6)

0 (0.0)

0 (0.0)

0.001 ‡

1 (2.1)

0 (0.0)

0 (0.0)

0.632‡

 MD

14 (50.0)

1 (7.1)

0 (0.0)

10 (20.8)

0 (0.0)

0 (0.0)

 PD

12 (42.9)

12 (85.7)

3 (50.0)

32 (66.7)

4 (80.0)

0 (0.0)

 SRC

1 (3.6)

1 (7.1)

3 (50.0)

5 (10.4)

1 (20.0)

0 (0.0)

T stage

 T1

6 (21.4)

1 (7.1)

0 (0.0)

0.002 †

7 (14.6)

0 (0.0)

0 (0.0)

0.121†

 T2

10 (35.7)

2 (14.3)

0 (0.0)

12 (25.0)

0 (0.0)

0 (0.0)

 T3

8 (28.6)

7 (50.0)

2 (33.3)

18 (37.5)

3 (60.0)

0 (0.0)

 T4

4 (14.3)

4 (28.6)

4 (66.7)

11 (22.9)

2 (40.0)

0 (0.0)

pTNM stage

 I

10 (35.7)

2 (14.)

0 (0.0)

0.023 †

10 (20.8)

0 (0.0)

0 (0.0)

0.068†

 II

10 (35.7)

6 (42.9)

2 (33.3)

23 (47.9)

2 (40.0)

0 (0.0)

 III

8 (28.6)

6 (42.9)

4 (66.7)

14 (29.2)

2 (40.0)

0 (0.0)

 IV

0 (0.0)

0 (0.0

0 (0.0)

1 (2.1)

1 (10.0)

0 (0.0)

Recurrence

 Absent

20 (71.4)

8 (57.1)

5 (57.1)

0.956†

34 (70.8)

2 (40.0)

0 (0.0)

0.193†

 Present

8 (28.6)

6 (42.9)

1 (16.7)

14 (29.2)

3 (50.0)

0 (0.0)

Total (n = 101)

H3S10 phosphorylation level of DRM ≤4 cm (n = 62)

p value

H3S10 phosphorylation level of DRM >4 cm (n = 39)

p value

Low (%), n = 24

Int. (%), n = 34

High (%), n = 4

Low (%), n = 33

Int. (%), n = 6

High (%), n = 0

WHO classification

 WD

1 (4.2)

0 (0.0)

0 (0.0)

0.0001 ‡

1 (3.0)

0 (0.0)

0 (0.0)

0.6‡

 MD

10 (41.7)

1 (2.9)

0 (0.0)

13 (39.4)

1 (16.7)

0 (0.0)

 PD

12 (4.2)

29 (85.3)

1 (25.0)

17 (51.5)

4 (66.7)

0 (0.0)

 SRC

1 (4.2)

4 (11.8)

3 (75.0)

2 (6.1)

1 (16.7)

0 (0.0)

T stage

 T1

5 (20.8)

3 (8.8)

0 (0.0)

0.009

6 (18.2)

0 (0.0)

0 (0.0)

0.287†

 T2

6 (25.0)

8 (23.5)

1 (25.0)

8 (24.2)

2 (33.3)

0 (0.0)

 T3

9 (37.5)

13 (38.2)

3 (75.0)

14 (42.4)

2 (33.3)

0 (0.0)

 T4

4 (16.7)

10 (29.4)

0 (0.0)

5 (15.2)

2 (33.3)

0 (0.0)

pTNM stage

 I

5 (20.8)

5 (14.7)

0 (0.0

0.361†

12 (36.4)

0 (0.0)

0 (0.0)

0.107†

 II

9 (37.5)

17 (50.0)

1 (25.0)

13 (39.4)

3 (50.0)

0 (0.0)

 III

10 (41.7)

11 (32.4)

3 (75.0)

7 (21.2)

3 (50.0)

0 (0.0)

 IV

0 (0.0)

1 (2.9)

0 (0.0)

1 (3.0)

0 (0.0)

0 (0.0)

Recurrence

 Absent

19 (79.2)

13 (38.2)

1 (25.0)

0.031 †

24 (72.7)

4 (66.7)

0 (0.0)

0.063†

 Present

5 (20.8)

21 (61.8)

3 (75.0)

9 (27.3)

2 (33.3)

0 (0.0)

  1. All three columns are compared in each category: †chi-square test by two-sided linear-by-linear association; ‡chi-square test by two-sided Fisher’s exact test. Italics indicates values that are statistically significant (<0.05)